Elevated nephrogenous cyclic adenosine monophosphate to monitor early renal osteodystrophy.
Radiographs, serum chemistries, parathyroid hormone (PTH), and nephrogenous cyclic adenosine monophosphate (cAMP) were evaluated in thirty-two children with normal serum creatinine, chronic renal insufficiency, chronic hemodialysis, and transplantation. Nephrogenous cAMP increases linearly with creatinine, and there is a good correlation (r = 0.89) between immunoreactive PTH (iPTH) and nephrogenous cAMP except for patients with severe renal insufficiency or requiring chronic hemodialysis. Elevated nephrogenous cAMP is evidence for metabolic bone disease earlier than usually recognized. Early measurements of iPTH and nephrogenous cAMP could ensure early therapeutic intervention which might alleviate renal osteodystrophy in chronic renal insufficiency and transplant patients.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000276:immunology / Q000652:urine*; D000242:Cyclic AMP / Q000652:urine*; D005260:Female; D006801:Humans; D007223:Infant; D007674:Kidney Diseases / Q000652:urine; D008297:Male; D010281:Parathyroid Hormone / Q000276:immunology; D011863:Radioimmunoassay
D010281:Parathyroid Hormone; D000242:Cyclic AMP